Lessons for other organizations
The trigger for transformation does not have to be a crisis. Novo Nordisk acted because success had outpaced its operating model – not because failure had forced change. Organizations that wait for a burning platform may find that by the time the pressure is undeniable, the habits they need to change are even more deeply entrenched.
The hardest part of transformation is changing how leaders see their role and their identity – not what they know. That shift requires sustained peer engagement, psychological safety, and shared purpose. Periodic reality checks – where an organization honestly assesses whether its leadership capabilities still match its strategic ambitions – are valuable, but only alongside the ongoing, living work of development that happens in between.
Leadership development programs disconnected from strategic context waste most of their potential. Commissioning directly from the part of the business carrying the challenge made a significant difference to the relevance and quality of what was built, and to the quality of sponsorship that gave the program room to evolve beyond its original scope.
That evolution points to perhaps the most undervalued lesson of all. When Novo Nordisk commissioned the program, its brief was clear and reasonable – but incomplete. It took a partner willing to look beyond what had been asked, and to conduct genuine diagnostic work before designing anything, to surface the hidden structural problem: the absence of peer learning among the GPT Chairs. The most valuable thing a development partner can offer is often not the program they were hired to deliver, but the diagnostic honesty to identify what was missing from the brief.
The most durable organizational change is change that involves people who own the outcome. The GPT Chairs at Novo Nordisk built something that outlasted the program – a community with a shared identity, a common voice, and the confidence to shape how Novo Nordisk develops its products for the future. That community’s success led Novo Nordisk to commission a comparable program for its US R&D organization in 2025. That is what transformation looks like when it works.
Read more about systems change in I by IMD‘s report The Future of Life Sciences – The new map of discovery, terms of competition, and the search for where value will lie.